# Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19

> **NCT05052008** · — · COMPLETED · sponsor: **Fayoum University** · enrollment: 90 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT05052008
- **Lead sponsor:** Fayoum University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-15
- **Primary completion:** 2021-08-10
- **Final completion:** 2021-09-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052008, "Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05052008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*